Lenvima Archives -

New phase 3 data have shored up the position of Merck & Co’s cancer immunotherapy Keytruda in the

Merck gets a leg-up for Keytruda in first-line kidney cancer

https://pharmaphorum.com/news/merck-gets-a-leg-up-for-keytruda-in-first-line-kidney-cancer/

The combination of Merck & Co’s Keytruda with targeted drug Lenvima has been approved for endometrial cancer in

Merck, Eisai get triple approvals for Keytruda/Lenvima combination

https://pharmaphorum.com/news/merck-eisai-get-triple-approvals-for-keytruda-lenvima-combination/

pharmaphorum interviews professor Jeff Evans, from the University of Glasgow’s Institute of Cancer Sciences, about findings of a

Raising the bar in liver cancer therapy

https://pharmaphorum.com/oncology/insights-oncology/raising-bar-liver-cancer-therapy/

Gary Hendler, chairman and CEO of EMEA region for Eisai, talked to Richard Staines at pharmaphorum about findings

Eisai’s EMEA CEO Gary Hendler on why quality of life is key to Lenvima’s success

https://pharmaphorum.com/oncology/insights-oncology/eisais-emea-ceo-gary-hendler-lenvimas-success/

Thyroid cancer drug falls through gap in NHS funding

Eisai angry over thyroid cancer drug impasse in England

https://pharmaphorum.com/news/eisai-furious-england-blocks-cancer-drug-funding/

Lenvima